Regulatory Story
Go to market news section View chart   Print
ReNeuron Group plc  -  RENE   

AIM Rule 17 Notification

Released 07:00 25-Feb-2013

RNS Number : 5599Y
ReNeuron Group plc
25 February 2013




25 February 2013



ReNeuron Group plc

("ReNeuron" or "the Company")


AIM Rule 17 Notification


Guildford, UK, 25 February 2013:  Pursuant to Rule 17 of the AIM Rules for Companies (the "AIM Rules"), ReNeuron Group plc (AIM: RENE.L) announces the following change to a director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules.


Paul Harper, a director of the Company, was a director of Angel Biotechnology plc ("Angel") until December 2012. On 11 February 2013, Angel announced that administrators had been appointed with immediate effect.  Accordingly, the Company is required to make this notification.





ReNeuron                                                                                  +44 (0) 1483 302560

Michael Hunt, Chief Executive Officer

Dr John Sinden, Chief Scientific Officer 


Buchanan                                                                                    +44 (0) 20 7466 5000

Mark Court, Fiona Henson, Sophie Cowles                                                          


Cenkos Securities                                                                      +44 (0) 20 7397 8900

Stephen Keys, Adrian Hargrave (NOMAD and Broker)

Andy Roberts (Sales)


About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  


ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa.


ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research.  The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.


ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at




This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


AIM Rule 17 Notification - RNS